Innovent Biologics, Inc.
IVBXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $9,422 | $6,206 | $4,556 | $4,270 |
| % Growth | 51.8% | 36.2% | 6.7% | – |
| Cost of Goods Sold | $1,510 | $1,807 | $931 | $573 |
| Gross Profit | $7,912 | $4,399 | $3,625 | $3,697 |
| % Margin | 84% | 70.9% | 79.6% | 86.6% |
| R&D Expenses | $2,681 | $2,228 | $2,871 | $2,478 |
| G&A Expenses | $738 | $750 | $835 | $884 |
| SG&A Expenses | $5,085 | $3,851 | $3,426 | $3,612 |
| Sales & Mktg Exp. | $4,347 | $3,101 | $2,591 | $2,620 |
| Other Operating Expenses | -$112 | $0 | -$90 | -$342 |
| Operating Expenses | $7,654 | $6,079 | $6,207 | $5,749 |
| Operating Income | -$756 | -$1,679 | -$3,123 | -$2,703 |
| % Margin | -8% | -27.1% | -68.5% | -63.3% |
| Other Income/Exp. Net | $0 | $535 | $952 | $62 |
| Pre-Tax Income | -$79 | -$1,144 | -$2,170 | -$2,642 |
| Tax Expense | $16 | -$116 | $9 | $87 |
| Net Income | -$95 | -$1,028 | -$2,179 | -$2,729 |
| % Margin | -1% | -16.6% | -47.8% | -63.9% |
| EPS | -0.058 | -0.66 | -1.46 | -1.88 |
| % Growth | 91.2% | 54.8% | 22.3% | – |
| EPS Diluted | -0.056 | -0.66 | -1.46 | -1.88 |
| Weighted Avg Shares Out | 1,577 | 1,560 | 1,490 | 1,451 |
| Weighted Avg Shares Out Dil | 1,627 | 1,560 | 1,490 | 1,456 |
| Supplemental Information | – | – | – | – |
| Interest Income | $423 | $453 | $190 | $152 |
| Interest Expense | $68 | $99 | $102 | $62 |
| Depreciation & Amortization | $276 | $385 | $319 | $205 |
| EBITDA | -$480 | -$661 | -$1,749 | -$2,375 |
| % Margin | -5.1% | -10.6% | -38.4% | -55.6% |